InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (5 ops.)
Insider track record
Board DirectorDisclosed buys
2
Disclosed sells
5
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Discover the detailed record of transactions filed by Svoronos Dawn, Director. Director active across 5 companies, notably PTC Therapeutics, INC.. Aggregated, 12 filings have been published. Breakdown: 2 buys · 5 sells. Total volume traded: €1.3m. Activity tracked since 9 June 2021. The latest transaction was disclosed on 24 August 2023 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Svoronos Dawn
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations12 total
5,000 sharesCommon StockSEC:0001574579-25-000004:0
15,000 sharesCommon StockSEC:0001962918-25-000054:0
25,000 shares@ US$38.70100.0% of flowCommon SharesSEC:0000950170-23-044403:0
15,000 shares@ US$18.00100.0% of flowCommon StockSEC:0001209191-23-028882:0
Canonical exit: 7 Aug 2023 (T+90)
5,376 sharesCommon StockSEC:0000899243-22-033157:0
1,908 shares@ US$27.2446100.0% of flowCommon StockSEC:0000899243-22-023597:0
3,600 sharesCommon StockSEC:0000899243-22-022889:0
738 shares@ US$27.2010.0003% mcap24.0% of flowCommon StockSEC:0001415889-22-006410:0
30,000 shares@ US$0.8526100.0% of flowCommon StockSEC:0001209191-22-030075:0
Canonical exit: 14 Aug 2022 (T+90)
510 shares@ US$38.52535.6% of flowCommon StockSEC:0001179110-22-000392:0
3,037 sharesCommon StockSEC:0000899243-21-025001:0
365 shares@ US$41.88525.7% of flowCommon StockSEC:0001179110-21-006598:0
12 of 12 declarations
About Svoronos Dawn
Svoronos Dawn is Administrateur and has filed 12 disclosures in total. Across the 12 sampled recent filings, the period runs from 2021-06-11 to 2025-12-10, with EUR 270748 of purchases and EUR 994105 of sales, and the modal transaction type is sale. The largest recent filings are a sale of EUR 895904.9923103858 in Xenon Pharmaceuticals Inc., a purchase of EUR 246245.4101960755 in ACELYRIN, Inc., and a sale of EUR 49353.93448769525 in Global Blood Therapeutics, Inc.
